CLOSED
GET A PIECE OF SCITECH DEVELOPMENT, L.L.C.
Advancing Cancer Treatment Through Safer Drug Delivery
Show more
$135,205.02 Raised
REASONS TO INVEST
TEAM
Earle Holsapple • CEO, President & Co-Founder
Read More
Andrew Stumpf • Chief Financial Officer (CFO)
Read More
Louis M. Scarmoutzos, Ph.D. • Chief Operating Officer
Read More
We Are Making A Difference
Wouldn’t it be great if every patient could “Ring the Bell” to signify the end of their cancer journey?We are SciTech Development, a Specialty Pharmaceutical Company with the goal of helping patients end their battle with cancer.
According to IQVIA, about 80% of the industry's drug development pipeline comes from emerging biopharma companies, which means small companies are overwhelmingly driving innovation and new drug products.
The first step to potentially curing cancer is to begin clinical trials of ST-001 for the treatment of lymphoma. Our intent is to expand the use of ST-001 in other cancers and develop additional new drugs so we can help the millions of patients that are battling cancer.
FDA approval of ST-001 would be a significant step towards becoming a revenue-generating company.
How It Works
*The above video contains computer generated demonstrations of the SciTech Drug Delivery Platform.
For more detailed technical info, visit our science-based website at www.scitechdevelopment.com
THE PROBLEM
Cancer is an Escalating Worldwide Problem
Billions of dollars have been spent on developing new cancer therapies. And yet, there have been limited advancements in treatment and healthcare costs continue to rise.
THE SOLUTION
An Effective Drug Delivery Platform for New Cancer Treatments
We believe that ST-001 will provide hope to millions of cancer patients.
- The SciTech Drug Delivery Platform or “SDP” is designed to safely deliver high concentrations of drugs to kill cancer cells.
- SDP works by formulating drugs into very tiny spheres known as “nanovesicles”, which “trick” the cells into letting the drug inside, ultimately killing the cancer.
- SDP can be engineered with other drugs, making them more effective and patentable.
- ST-001 nanoFenretinide, our patented lead drug candidate, is a combination of the Delivery Platform and fenretinide, a drug with a well-documented safety profile.
- ST-001 and newly engineered SDP drugs may be used alone or in combination with existing therapies.
THE MARKET
New Therapeutics for Broader and Better Clinical Outcomes
Oncology is the world’s largest pharmaceutical therapeutic area. The growing prevalence of cancer around the world will continue to spur opportunities for the oncology drug market. SciTech plans to engineer new cancer drugs for better clinical outcomes in more oncology areas and diseases.
The market potential can be expanded to $5B-25B+ with ST-001 combination therapies, targeting other cancer indications, and from using our Delivery Platform to engineer and patent new drugs.
Our Traction
SciTech Anticipates a Rapid Path to Commercialization
Fenretinide: Safe with Great Promise in Previous Clinical Trials
ST-001 contains the active ingredient fenretinide, a drug with a well-documented safety profile in over 3000 patients. However, it does not easily dissolve in the body so it cannot get to the cancer cells in high enough doses to be effective, a problem solved by ST-001.
After achieving numerous milestones, our approved clinical trials are “Confirmatory” not “Exploratory”. Our trial simply needs to confirm that ST-001 can transport the drug into the cancer cell safely, at the right dose, without toxic side effects, and provide beneficial patient outcomes.
Unlike other “typical” clinical trials, the FDA has provided SciTech with guidance to a much faster pathway requiring fewer patients. Once the clinical trials are completed and with FDA approval SciTech will be able to commercialize ST-001.
SciTech can now begin its clinical trial at Rush University Medical Center in Chicago, IL.
how we're different
SciTech Can Develop a Robust Commercial Pipeline Using SDP, Our Proprietary Drug Delivery Platform
- Our revolutionary new Drug Delivery Platform (SDP) has enormous potential in developing and delivering new drugs.
- ST-001 is clinical trial ready with a rapid path to commercialization.
- ST-001 is an affordable cancer therapy that can reduce treatment costs and improve outcomes.
- SciTech has an exceptional leadership and scientific advisory team with vast industry experience.
THE BUSINESS MODEL
Milestone Driven With Multiple Exit Strategies
Our immediate goal is to commercialize ST-001 and develop strategic partnerships with companies in the pharmaceutical industry who are looking to expand their existing drug portfolio in oncology, target new diseases, or develop combination drug therapies.
ST-001 would be an ideal candidate for use in combination drug/therapy regimens. The emerging trend in cancer treatment is to combine new, targeted therapies with other drugs in order to increase their effectiveness and therapeutic benefit. Use of ST-001 in this manner would have a significant positive impact on revenue.
SciTech can develop a robust pipeline of new drug candidates using our Delivery Platform, potentially increasing the valuation of the company.
All potential exit strategies will be considered, based on the best outcome for our investors, the company, and the timing of these potential options.
Due to the COVID-19 pandemic, the company is currently working virtually. We have engaged a large-scale drug manufacturer to produce ST-001 and a clinical trial site to conduct our study.
WHY INVEST
Together, We Can Fight Cancer and Bring New Hope to Patients Around the World.
First and foremost, we believe that ST-001 may drastically improve the therapeutic options for cancer patients. Whether it's you, a family member, or a friend, just about everyone has been touched by cancer. Too many of us have too many common stories of pain and sorrow.
FDA approval of ST-001 would be a significant step toward becoming a revenue-generating company.
With our science and your help, we can provide a brighter future for patients, our partners, and our investors.
Please join us in helping to give each and every cancer patient a fighting chance to “Ring the Bell’’!
ABOUT
HEADQUARTERS
P.O. Box 36927
Grosse Pointe Farms, MI 48236
WEBSITE
View Site
TERMS
SciTech Development, L.L.C.
Overview
PRICE PER SHARE
$2.75
DEADLINE
Jul. 30, 2022 at 6:59 AM UTC
VALUATION
$63.93M
FUNDING GOAL
$10K - $5M
Breakdown
MIN INVESTMENT
$275
MAX INVESTMENT
$4,999,997.75
MIN NUMBER OF SHARES OFFERED
3,636
MAX NUMBER OF SHARES OFFERED
1,818,181
OFFERING TYPE
Equity
SHARES OFFERED
Units
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum Number of Units Offered subject to adjustment for bonus units. See Bonus info below.
Company Perks
Time-Based Bonuses*:
- Invest within the 1st week and receive 20% bonus shares.
- Invest within the 2nd week and receive 15% bonus shares.
- Invest within the 3rd week and receive 10% bonus shares.
- Invest within the 4th week and receive 5% bonus shares.
Volume Based Bonuses and Perks*:
Tier 1
- Invest >$500, you will receive 5% bonus shares.
Tier 2
- If you invest >$1,500, you will receive 10% bonus shares.
Tier 3
- If you invest >$5,000, you will receive 15% bonus shares.
Tier 4
- If you invest >$10,000, you will receive 20% bonus shares and an in-person** or virtual meeting with the leadership team.
*Investors cannot qualify for both bonuses in any single investment. If an investor qualifies for two bonuses the higher of the two bonuses will be applied. All perks occur after the offering is completed.
**Travel Not Included
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
SciTech Development LLC will offer 10% additional bonus Units for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine members will receive a 10% bonus for any units they purchase in this offering. For example, if you buy 100 Units at $2.75/unit, you will receive 110 Units, meaning you'll own 110 shares for $275. Fractional Units will not be distributed and unit bonuses will be determined by rounding down to the nearest whole unit.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Insider Investment Notice
Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.
Irregular Use of Proceeds
ALL UPDATES
08.05.22
Your StartEngine SciTech Development Investment
07.30.22
Thank You
07.29.22
LAST CHANCE – ONLY HOURS LEFT TO INVEST!
07.28.22
Fenretinide as a Potential Treatment for Brain Cancer
A recent publication suggests a combination therapy (which includes fenretinide) as a potential treatment for DIPG (diffuse intrinsic pontine glioma), a type of childhood brain cancer that is always fatal (https://bit.ly/3vk0u9T).
An earlier Phase 2 clinical study of fenretinide in adults with brain cancer showed that fenretinide was inactive at the dosage used in that clinical trial. The authors of the study further relay that additional studies are warranted based on the tolerability of the agent and the potential for activity at a higher fenretinide dosage, as suggested in the trial (https://bit.ly/3RYhnjU).
The impact of a brain cancer diagnosis is significant and can affect the quality of life through disease progression as well as by the effects of the treatment. Current treatment primarily includes surgery, radiation therapy and chemotherapy, with low survival rates (https://bit.ly/3vlUgpX).
Famous people who have succumbed to brain cancer include John McCain, Ted Kennedy, Lou Rawls, Pete Rozelle, Celia Cruz, Mary Shelley, Slim Pickens, Bobby Bonds, Gene Siskel (of Siskel & Ebert fame), Ethel Merman, and George Gershwin to name a few (https://bit.ly/3PY0x2N).
SciTech’s ST-001 nanoFenretinide drug candidate offers the potential of a bioavailable, non-toxic, and affordable treatment for brain cancer.
Visit www.SciTechSDP.com to learn more about ST-001 nanoFenretinide and SciTech’s proprietary technology.
07.28.22
One Day Left to Invest in SciTech
There’s so little time left to join our Investor Family – but you can still do it!
Make your investment at startengine.com/scitechdevelopment
Visit www.SciTechSDP.com to learn more about SciTech.
07.27.22
Only Two Days Left to Invest in SciTech
Right now is the perfect time for you to make your best decision of the day... with an investment in SciTech!
Only 2 days left in our crowdfunding campaign at startengine.com/scitechdevelopment
Visit www.SciTechSDP.com to learn more about SciTech.
07.26.22
Fenretinide Treatment for Obesity and Type 2 Diabetes – 3 Days Left to Invest –
A recent publication demonstrated that fenretinide can prevent obesity and improve insulin sensitivity in mice. The authors of the publication discuss the beneficial effects of fenretinide's multiple mechanisms of action. However, despite all the beneficial effects of fenretinide, they did observe increased atherosclerosis in their LDLR-/- mutated mouse models, models for studying familial (genetic) hypercholesterolemia (high cholesterol). https://doi.org/10.1101/2022.07.22.500933
An earlier publication demonstrated that fenretinide and metformin exhibited positive individual and synergistic effects when administered to treat diabetes in a rat model. https://doi.org/10.1080/26895293.2020.1732483
The recent publications suggest that SciTech's ST-001 nanoFenretinide technology may present additional out-licensing opportunities.
07.26.22
You Only Have The Next Three Days To Invest
Hurry! There are only three (3) days left to invest in SciTech.
Invest what you can at startengine.com/scitechdevelopment
Visit www.SciTechSDP.com to learn more about SciTech and its proprietary technology.
07.25.22
Only Four Days Left to Invest
Keep calm - only four (4) days left to invest in SciTech at startengine.com/scitechdevelopment
Visit www.SciTechSDP.com to learn more about SciTech and its proprietary technology.
07.25.22
Only Five Days Left to Invest
Only five (5) days left to invest in our crowdfunding campaign on StartEngine.
Don't miss your chance to be part of our investor community! Invest Now at startengine.com/scitechdevelopment
Visit www.SciTechSDP.com to learn more about SciTech and its proprietary technology.
REWARDS
Venture Club
Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).
JOIN THE DISCUSSION
0/2500
Salvador Avalos
3 years ago
How does the prevalence of Statin medications impact your delivery platform? Could you provide details on your approach regarding Statins?
Show more
1
0
Jerry Irwin
3 years ago
when does your raise close?
1
0
Steve Mills
3 years ago
From recent update: "..since sophisticated, accredited investors are willing to invest larger sums of money." For myself and all my fellow 'rube' investors on Start Engine, I say, "Ouch!" : )
Show more
2
0
Anne Oshman
3 years ago
I do not see anyone listed as an employee of the company involved in this study of nanofenretinide. "Orienti, I., Francescangeli, F., De Angelis, M.L. et al. A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. Cell Death Dis 10, 529 (2019). https://doi.org/10.1038/s41419-019-1775-y." What involvement, if any, did the company have with this study?
Show more
2
0
Anne Oshman
3 years ago
Does the company own the patent to the SDP delivery system? Are there any royalty payments due to any third parties? Likewise, does the company own the patent for ST-001? Are there any royalty payments due to any third parties for use of the underlying fenretinide?
Show more
4
0
Joseph Kraus
3 years ago
Just curious- given that the campaign has just been live for only a few weeks, why does the company dashboard indicate your campaign has "14 Days Left" when it seems as though you have just begun? Doesn't make sense to me. Thanks.
Show more
1
0
David Schaffer
3 years ago
SciTech would like to thank all of the early investors for joining us on this mission to fight and defeat cancer. We are very appreciative of the early investor support and confidence in this significant opportunity that has enabled the Start Engine offering to achieve its first funding milestone surpassing $45k raised on the platform. Our sights are now set on toppling the next milestone of $75k. Thank you!!!! again!
Show more
0
1
alex boosalis
3 years ago
On Page 29 of the Offering Memorandum, you mention Trillium and its 128mm Valuation at pre phase 1 trial (which is the same spot you are in now) . How is your “therapeutics” similar to Trillium....
Show more
2
0
Barend Venter
3 years ago
I would like to understand why this delivery method kills cancer cells and not other cells. Is there a reference you can add to your pitch that will clear this up?
Show more
2
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
FAQS
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Earle Holsapple
3 years ago
A special thanks to those investors who have contributed to this wonderful cause and opportunity or those who have been following us. SciTech is on track to test its promising drug in humans in Q4. Your help in enabling that trial is greatly appreciated. As we close this campaign, keep following us at SciTechsdp.com. Regards, Earle Holsapple, President
Show more
0
0